Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
Kentaro NishiMasao OguraNaotaka TamaiMasafumi GimaKentaro IdeGoro KoinumaKoichi KameiShuichi ItoPublished in: Pediatric rheumatology online journal (2022)
Our literature review suggest that JDM with RP-ILD has a high mortality rate. In JDM, rituximab may be a promising treatment option for RP-ILD. In the future, the efficacy of rituximab in the early phases of ILD should be investigated.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- diffuse large b cell lymphoma
- hodgkin lymphoma
- multiple sclerosis
- chronic lymphocytic leukemia
- cardiovascular disease
- cell death
- cardiovascular events
- systemic lupus erythematosus
- case report
- mass spectrometry
- high resolution